Herein, we predicted that NSC765689 could successfully target GSK3β, β-Catenin, STAT3, and CD44 oncogenic signaling, showing its potential role in regulating expressions of these oncogenic signatures in GBM. This evidence concerns the gene STAT3 and glioblastoma.